In contrast, elocalcitol, a 1-α-fluor-substituted, non-hypercalcemic vitamin D derivative, has about 10 times lower efficacy for VDR (Peleg et al., 2002), and, therefore, it is reasonable to propose that the preventive action of elocalcitol on obesity is mediated via targets other than the VDR. Here, VDR is linked to obesity disorder.